STRENGTHENING HUMAN IMMUNITY USING ROBUST ANTIBODY THERAPIES
SparX Biopharmaceutical Corp.
Cure Cancer by Targeting Multiple Pathways with the Right Therapeutic Strategy
SPARX BIFUNCTIONAL ADC PLATFORM
Universally empowering ADCs with high specificity, sensitivity and activity
Chicago, USA January 17, 2022
With a mission of “Bolstering human immunity by utilizing empowered antibody therapies”, the SparX Group announced that the FDA has approved their IND application for
Fosun veteran Juxiang Xia joins Sparx Therapeutics
August 10th, 2021 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibody and antibody-drug conjugate (ADC) drugs, today announced the appointment of Ms. Juxiang
Former Eli Lilly veteran Dr. Victor Wroblewski joins Sparx Therapeutics as a Senior VP and Head of Biology
Chicago，USA September 1, 2020 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibodies to treat solid tumors, today announced the appointment of Dr.
Sparx Therapeutics-News release 2018-11-8
Sparx Therapeutics & KPC Pharmaceutical Sign Agreement for the Development of anti-Claudin 18.2 Antibodies Sparx Therapeutics, Inc. has signed an agreement with KPC Pharmaceutical to
Precision Medicine Center Unveiled
China, Sep-10-2018 Central South University Xiangya – Yaoyuan Pharma Precision Medicine Research Center has just been officially founded today. This is yet another newly established